Oral insulin-mimetic compounds that act independently of insulin

Diabetes

Volumn 56, Issue 2, 2007, Pages 486-493

  García Vicente, Silvia ^a,b   Yraola, Francesc ^b   Marti, Luc ^a,c   González Muñoz, Elena ^a,b   García Barrado, María José ^d   Cantó, Carles ^b   Abella, Anna ^a   Bour, Sandy ^e   Artuch, Rafael ^f   Sierra, Cristina ^f   Brandi, Nuria ^f   Carpéné, Christian ^e   Moratinos, Julio ^d   Camps, Marta ^a,b   Palacín, Manuel ^a,b   Testar, Xavier ^a,b   Gumà, Anna ^b   Albericio, Fernando ^a,b   Royo, Miriam ^b   Mian, Alec ^c   Zorzano, Antonio ^a,b   more..

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Genmedica Therapeutics   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e INSERM   (France)

^f University of Barcelona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM VANADATE; GLYCOGEN SYNTHASE KINASE 3; HEXAKIS(BENZYLAMMONIUM)DECAVANADATE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PENTAKIS(BENZYLAMMONIUM)DECAVANADATE; PROTEIN KINASE B; TETRAKIS(BENZYLAMMONIUM)DECAVANADATE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 33847018785     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-0269     Document Type: Article

References (41)

1. Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou JH, Masiarz F, Kan YW, Goldfine ID: The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40:747-758, 1985
2. Hubbard SR, Wei L, Ellis L, Hendrickson WA: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372:746-754, 1994
3. Hubbard SR: Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16:5572-5581, 1997
4. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313:756-761, 1985
5. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269:1-4, 1994
6. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV: Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3, 4, 5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes 52:1926-1934, 2003
7. Caro JF, Sinha MK, Raju SM, Ittoop O, Pories WJ, Flickinger EG, Meelheim D, Dohm GL: Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 79:1330-1337, 1987
8. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95:2195-2204, 1995
9. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB: Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741, 1999
10. Olefsky JM, Ciaraldi TP, Kolterman OG: Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med 79:12-22, 1985
11. Tritos NA, Mantzoros CS: Clinical review 97: syndromes of severe insulin resistance. J Clin Endocrinol Metab 83:3025-3030, 1998
12. Vestergaard H, Lund S, Pedersen O: Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. J Intern Med 250:406-414, 2001
13. Abella A, Marti L, Camps M, Claret M, Fernandez-Alvarez J, Gomis R, Guma A, Viguerie N, Carpene C, Palacin M, Testar X, Zorzano A: Semicarbazide- sensitive amine oxidase/vascular adhesion protein-1 activity exerts an antidiabetic action in Goto-Kakizaki rats. Diabetes 52:1004-1013, 2003
14. Marti L, Abella A, Carpene C, Palacin M, Testar X, Zorzano A: Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. Diabetes 50:2061-2068, 2001
15. Enrique-Tarancon G, Marti L, Morin N, Lizcano JM, Unzeta M, Sevilla L, Camps M, Palacin M, Testar X, Carpene C, Zorzano A: Role of semicarbazide- sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem 273:8025-8032, 1998
16. Marti L, Morin N, Enrique-Tarancon G, Prevot D, Lafontan M, Testar X, Zorzano A, Carpene C: Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide. J Pharmacol Exp Ther 285:342-349, 1998
17. Abella A, Garcia-Vicente S, Viguerie N, Ros-Baro A, Camps M, Palacin M, Zorzano A, Marti L: Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 47:429-438, 2004
18. Boden G, Chen X, Ruiz J, van Rossum GD, Turco S: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45:1130-1135, 1996
19. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95:2501-2509, 1995
20. Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, Redondo JC: Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 86:1410-1417, 2001
21. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR: Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab 80:3311-3320, 1995
22. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45:659-666, 1996
23. Domingo JL: Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. Biol Trace Elem Res 88:97-112, 2002
24. Gil J, Miralpeix M, Carreras J, Bartrons R: Insulin-like effects of vanadate on glucokinase activity and fructose 2, 6-bisphosphate levels in the liver of diabetic rats. J Biol Chem 263:1868-1871, 1988
25. Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227:1474-1477, 1985
26. Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats: characterization and mode of action. J Biol Chem 262:6658-6662, 1987
27. Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 188:73-80, 1998
28. Johnson DR, O'Connor JC, Dantzer R, Freund GG: Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. Proc Natl Acad Sci U S A 102:15184-15189, 2005
29. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B: Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282:E834-E842, 2002
30. Enrique-Tarancon G, Castan I, Morin N, Marti L, Abella A, Camps M, Casamitjana R, Palacin M, Testar X, Degerman E, Carpene C, Zorzano A: Substrates of semicarbazide-sensitive amine oxidase co-operate with vanadate to stimulate tyrosine phosphorylation of insulin-receptor-substrate proteins, phosphoinositide 3-kinase activity and GLUT4 translocation in adipose cells. Biochem J 350:171-180, 2000
31. Visentin V, Prevot D, Marti L, Carpene C: Inhibition of rat fat cell lipolysis by monoamine oxidase and semicarbazide-sensitive amine oxidase substrates. Eur J Pharmacol 466:235-243, 2003
32. Marti L, Abella A, De La Cruz X, Garcia-Vicente S, Unzeta M, Carpene C, Palacin M, Testar X, Orozco M, Zorzano A: Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: identification of novel substrates with insulin-like activity. J Med Chem 47:4865-4874, 2004
33. Salmi M, Yegutkin GG, Lehvonen R, Koskinen K, Salminen T, Jalkanen S: A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14:265-276, 2001
34. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
35. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, Rabasa-Lhoret R, Wallberg-Henriksson H, Laville M, Palacin M, Vidal H, Rivera F, Brand M, Zorzano A: Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism: a novel regulatory mechanism altered in obesity. J Biol Chem 278:17190-17197, 2003
36. Artuch R, Colome C, Sierra C, Brandi N, Lambruschini N, Campistol J, Ugarte D, Vilaseca MA: A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem 37:198-203, 2004
37. Badcock NR, Zoanetti GD, Martin ES: Nonchromatographic assay for malondialdehyde-thiobarbituric acid adduct with HPLC equivalence. Clin Chem 43:1655-1657, 1997
38. Jian K, Fok E, Cam MC, Sambandam N, Yao J, Rodrigues B: Susceptibility of spontaneously hypertensive rats to the diabetogenic effects of streptozotocin. Can J Physiol Pharmacol 74:1215-1221, 1996
39. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS: Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269:4596-4604, 1994
40. Trumbo P, Yates AA, Schlicker S, Poos M: Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc 101:294-301, 2001
41. Pouwels MJ, Tack CJ, Hermus AR, Lutterman JA: Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant type 2 diabetic patients. Diabet Med 20:76-79, 2003